



350-4243 Glanford Ave.  
Victoria, BC V8Z 4B9  
Tel: 250-744-2811  
Fax: 250-744-3331

## **STRESSGEN ADDS NEW MEMBER TO BOARD TO STRENGTHEN CLINICAL AND REGULATORY EXPERTISE FOR THE ADVANCEMENT OF HspE7 TO COMMERCIALIZATION**

FOR IMMEDIATE RELEASE

October 24, 2001

**San Diego, CA, October 24, 2001** - Stressgen Biotechnologies Corporation (TSE:SSB) announced today that Joann L. Data, M.D., Ph.D. has been appointed to the Board of Directors effective October 1, 2001. This brings the total Board membership to ten members.

Dr. Data has 26 years of experience with large pharmaceutical and biotech companies and has led successful clinical development and regulatory programs in both North America and international markets. Currently Dr. Data is the Senior Vice President of Regulatory Affairs and Quality Assurance with Amylin Pharmaceuticals, a position she has held since 1999. Dr. Data led the preparation of the regulatory application for registration of Amylin's lead product Symlin™ for both type 1 and type 2 diabetes in both the U.S. and Europe.

Prior to Dr. Data's experience in biotech, she held a number of key positions in both big pharma and academia. For six years, Dr. Data held numerous positions with The Upjohn Company, the most recent of which was Corporate Vice President for Worldwide Pharmaceutical Regulatory Affairs and Project Management. She also held a number of positions over an eight-year period at Hoffmann-La Roche, including Vice President of Clinical Research and Development. Since 1982, Dr. Data has been an adjunct assistant professor in medicine and pharmacology at Duke University Medical Center and at Cornell Medical Center since 1986. She earned her M.D. from Washington University School of Medicine and her Ph.D. in Pharmacology from Vanderbilt University.

"Dr. Data's experience in both North American and international markets adds significant depth to the Board as Stressgen continues to evolve as a late-stage biotechnology company," said William A. Cochrane, M.D., Chairman of the Board of Directors of Stressgen.

"We're obviously very pleased to have Dr. Data join the Board," said Daniel L. Korpilinski, President and Chief Executive Officer of Stressgen. "Her extensive global experience in the clinical and regulatory fields will be invaluable for the strategic advancement of our late-stage clinical program for HspE7 and subsequent regulatory filing with the FDA."

We will discuss Dr. Data's appointment, our third quarter 2001 financial results and the Company's progress during the upcoming conference call scheduled for October 25, 2001.

About Conference Call

Stressgen's conference call will be held on October 25, 2001 at 4:00 p.m. Eastern Time (1:00 p.m. Pacific Time). The dial in number to access the call is: 888-303-1409 in North America. A replay of this call will be available from October 25 at 3:00 p.m. Pacific Time through November 1, 2001. The playback number is: 800-558-5253, reservation No. 19842968. The Company will retain information about accessing the call on its website at [www.stressgen.com](http://www.stressgen.com) through the playback period.

About Stressgen

Stressgen is a public biopharmaceutical company focused on the development and commercialization of innovative stress protein-based immunotherapeutics. The Company is developing a broad range of products for the treatment of viral infections and related cancers. In addition to targeting HspE7 for HPV-related diseases, the Company also has a program to evaluate stress protein fusions in hepatitis B and several other indications. Stressgen is also an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology used by scientists worldwide.

HspE7 is a novel immunotherapeutic for the treatment of diseases caused by the human papillomavirus ("HPV"), one of the most common sexually transmitted diseases, estimated to infect approximately 30 to 50 percent of the sexually active population. There are 5.5 million new cases of genital HPV infection diagnosed per year in the U.S. alone, of which over 1 million represent cases of genital warts. In addition to warts, genital HPV infection can cause cervical cancer and a variety of precancerous conditions, including anal and cervical dysplasia.

*This news release contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding the development and commercialization of therapeutics for viral infections, cancers and other diseases. Factors that may cause our ultimate results or performance to be materially different from those implied by such forward-looking statements include risks that the products are not demonstrated to be safe or effective for their intended use, that the company will not obtain approval to market its products, and that there will be delays in proceeding from research to commercialization. These factors and others are more fully discussed in our filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities.*

-30-

Contacts:

Donna Slade  
Director, Investor Relations  
4445 Eastgate Mall, 2<sup>nd</sup> Floor  
San Diego, CA USA 92121  
Tel: 858/812-5616  
Fax: 858/812-5613  
[dslade@stressgen.com](mailto:dslade@stressgen.com)

Jennifer Matterson  
Communications Coordinator  
350-4243 Glanford Avenue  
Victoria, BC CANADA V8Z 4B9  
Tel: 250/744-2811  
Fax: 250/744-3331  
[jmatterson@stressgen.com](mailto:jmatterson@stressgen.com)

###